Acadia (ACAD) Announces Senior Management Appointments In Manufacturing, Quality, Compliance, Access And Reimbursement And Business Development

SAN DIEGO--(BUSINESS WIRE)--ACADIA Pharmaceuticals Inc. (NASDAQ: ACAD), a biopharmaceutical company focused on the development and commercialization of innovative medicines that address unmet medical needs in neurological and related central nervous system disorders, today announced the following senior management appointments:

•James A. Nash, Senior Vice President, Technology Development and Operations